Scinai Immunotherapeutics Ltd (SCNI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.123x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.45 Million) by net assets ($11.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Scinai Immunotherapeutics Ltd to measure how much of total assets are equity-financed.
Scinai Immunotherapeutics Ltd - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Scinai Immunotherapeutics Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mulberry Group PLC
LSE:MUL
|
0.375x |
|
WEST ISLAND BRANDS INC.
F:39N0
|
N/A |
|
AWILCO DRILLING PLC(SNDR)
F:0AI1
|
N/A |
|
EKF Diagnostics Holdings Plc
LSE:EKF
|
0.068x |
|
ULTRA LITHIUM
F:QFB
|
-0.007x |
|
Eason Technology Limited
NYSE MKT:DXF
|
0.000x |
|
NamR SA
PA:ALNMR
|
-0.280x |
|
Modiin Energy-Limited Partnership
TA:MDIN-L
|
0.177x |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Scinai Immunotherapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.10 Million | $-6.03 Million | -0.744x | -17.22% |
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -252.16% |
| 2020-12-31 | $-4.54 Million | $-22.57 Million | 4.970x | +319.55% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more